Literature DB >> 28857154

Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary.

Ariane K Kawata1, Ray Hsieh1, Randall Bender1, Shannon Shaffer1, Dennis A Revicki1, Martha Bayliss2, Dawn C Buse3, Pooja Desai4, Sandhya Sapra4, Brian Ortmeier4, Asha Hareendran5.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the measurement properties of the Migraine Physical Function Impact Diary (MPFID), a novel patient-reported outcome (PRO) measure for assessing the impact of migraine on physical functioning.
METHODS: In a prospective, observational study, adults with episodic migraine (EM) or chronic migraine (CM) used an eDiary to complete the MPFID (assessing daily impacts of migraine on physical function) and a headache diary (capturing migraine days, migraine pain intensity, and migraine interference) each day, and other PRO instruments related to migraine. Item-level evaluation, item response theory (IRT), and exploratory factor analysis (EFA) methods were applied to identify domains, select final MPFID items, and develop scoring procedures. Psychometric properties of the final 13-item MPFID were evaluated using confirmatory factor analysis and tests of reliability (Cronbach's α for internal consistency and intra-class correlation [ICC] for test-retest) and validity (convergent and known-groups).
RESULTS: The study enrolled 569 adults with chronic or episodic migraine, mean (SD) age 39.9 (12.0) years and 87.2% female. Item-level analyses based on interim data informed selection of a set of 13 items for the MPFID, through evaluation of floor/ceiling effects, item-to-item correlations, factor loadings, and IRT-based fit/misfit statistics. Two domain scores (EA: Impact on Everyday Activities; PI: Physical Impairment) and a global item score for impact on everyday activities were identified. EA and PI domains exhibited high internal consistency (α = 0.97; α = 0.93) and good test-retest reliability among stable subjects (ICCs = 0.74 and 0.77). Convergent validity was demonstrated by moderate correlations (r = ±0.50-0.68; P < .0001) between MPFID domain scores and number of migraine days, headache days, bed days, and other migraine-related PRO instruments. EA and PI scores differentiated between groups who varied by number of migraine days, migraine interference levels, migraine pain intensity, and median split groups of scores based on other PROs instruments (P < .05).
CONCLUSIONS: The MPFID has robust psychometric properties (ie, reliability and validity). Findings supported two distinct domains about the impact of migraine on physical functioning: Impact on Everyday Activities and Physical Impairment. Both domain scores showed evidence of excellent reliability and construct validity in assessing the impacts of migraine on physical functioning.
© 2017 American Headache Society.

Entities:  

Keywords:  diary; disability; function; headache; impact; impairment; instrument; measurement; migraine; patient-reported outcome; physical function; psychometrics; reliability; validity

Mesh:

Year:  2017        PMID: 28857154     DOI: 10.1111/head.13162

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  14 in total

1.  Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Authors:  Simona Lattanzi; Francesco Brigo; Eugen Trinka; Fabrizio Vernieri; Tommaso Corradetti; Mauro Dobran; Mauro Silvestrini
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

2.  The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy.

Authors:  Kelly M Wawrzyniak; Matthew Finkelman; Michael E Schatman; Ronald J Kulich; Valerie F Weed; Eura Myrta; David J DiBenedetto
Journal:  J Pain Res       Date:  2019-06-10       Impact factor: 3.133

3.  Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ).

Authors:  Ariane K Kawata; Asha Hareendran; Shannon Shaffer; Sally Mannix; Andrew Thach; Pooja Desai; Daniel D Mikol; Brian Ortmeier; Martha Bayliss; Dawn C Buse
Journal:  Headache       Date:  2019-06-05       Impact factor: 5.887

Review 4.  How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice.

Authors:  Cindy Tiseo; Raffaele Ornello; Francesca Pistoia; Simona Sacco
Journal:  J Headache Pain       Date:  2019-05-06       Impact factor: 7.277

5.  A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.

Authors:  Fumihiko Sakai; Takao Takeshima; Yoshihisa Tatsuoka; Koichi Hirata; Robert Lenz; Yi Wang; Sunfa Cheng; Toshiyasu Hirama; Daniel D Mikol
Journal:  Headache       Date:  2019-10-14       Impact factor: 5.887

6.  A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.

Authors:  Messoud Ashina; David Doležil; Jo H Bonner; Lifen Zhou; Jan Klatt; Hernan Picard; Daniel D Mikol
Journal:  Cephalalgia       Date:  2020-11-24       Impact factor: 6.292

7.  Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study.

Authors:  Peter J Goadsby; Uwe Reuter; Michel Lanteri-Minet; Gabriel Paiva da Silva Lima; Peggy Hours-Zesiger; Chrystel Fernandes; Shihua Wen; Nadia Tenenbaum; Aditi Kataria; Michel D Ferrari; Jan Klatt
Journal:  Neurology       Date:  2021-04-28       Impact factor: 9.910

8.  Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.

Authors:  Gian Luca Di Tanna; Joshua K Porter; Richard B Lipton; Anthony J Hatswell; Sandhya Sapra; Guillermo Villa
Journal:  Health Qual Life Outcomes       Date:  2019-11-12       Impact factor: 3.186

9.  The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.

Authors:  Gregor Broessner; Uwe Reuter; Jo H Bonner; David W Dodick; Yngve Hallström; Hernan Picard; Feng Zhang; Robert A Lenz; Jan Klatt; Daniel D Mikol
Journal:  Headache       Date:  2020-08-26       Impact factor: 5.887

10.  Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.

Authors:  Hans Christoph Diener; Messoud Ashina; Isabelle Durand-Zaleski; Tobias Kurth; Michel Lantéri-Minet; Richard B Lipton; Daniel A Ollendorf; Patricia Pozo-Rosich; Cristina Tassorelli; Gisela Terwindt
Journal:  Cephalalgia       Date:  2021-01-20       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.